07:53 AM EST, 11/26/2024 (MT Newswires) -- Amgen ( AMGN ) said Tuesday a phase 2 study showed that its investigational obesity drug MariTide caused an up to 20% average weight loss after a year in people living with obesity or overweight without type 2 diabetes without plateauing.

The study also showed that patients with type 2 diabetes achieved up to 17% average weight loss, also without plateauing, Amgen ( AMGN ) said.

The company said it is currently working on a second part of the study to evaluate any further weight loss with continued treatment after 52 weeks.